Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | calcium channel, voltage-dependent, T type, alpha 1H subunit | Starlite/ChEMBL | No references |
Homo sapiens | neuropeptide S receptor 1 | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | malate and lactate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Plasmodium vivax | lactate dehydrogenase | 0.0631 | 1 | 1 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0631 | 1 | 1 |
Echinococcus multilocularis | neuropeptide s receptor | 0.0558 | 0.8292 | 0.8129 |
Mycobacterium tuberculosis | Probable malate dehydrogenase Mdh | 0.0245 | 0.0871 | 0.5 |
Trypanosoma cruzi | cytosolic malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Echinococcus granulosus | L lactate dehydrogenase | 0.0385 | 0.4195 | 0.3641 |
Mycobacterium ulcerans | malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Entamoeba histolytica | malate dehydrogenase, putative | 0.0631 | 1 | 1 |
Trypanosoma cruzi | glycosomal malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Toxoplasma gondii | malate dehydrogenase MDH | 0.0631 | 1 | 0.5 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0631 | 1 | 1 |
Trypanosoma brucei | glycosomal malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Echinococcus granulosus | lactate dehydrogenase protein | 0.0631 | 1 | 1 |
Plasmodium falciparum | malate dehydrogenase | 0.0631 | 1 | 1 |
Trypanosoma cruzi | glycosomal malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Giardia lamblia | Malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Echinococcus granulosus | L lactate dehydrogenase B chain | 0.0631 | 1 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Trypanosoma cruzi | malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Loa Loa (eye worm) | malate dehydrogenase | 0.0245 | 0.0871 | 0.0742 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0631 | 1 | 1 |
Trypanosoma brucei | mitochondrial malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase protein | 0.0631 | 1 | 1 |
Echinococcus granulosus | lactate dehydrogenase a | 0.0631 | 1 | 1 |
Brugia malayi | Malate dehydrogenase, cytoplasmic | 0.0245 | 0.0871 | 0.0742 |
Chlamydia trachomatis | malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Trypanosoma cruzi | malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0631 | 1 | 1 |
Mycobacterium leprae | PROBABLE MALATE DEHYDROGENASE MDH | 0.0245 | 0.0871 | 0.5 |
Toxoplasma gondii | lactate dehydrogenase LDH2 | 0.0631 | 1 | 0.5 |
Trypanosoma cruzi | mitochondrial malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Trypanosoma brucei | malate dehydrogenase-related | 0.0245 | 0.0871 | 0.5 |
Echinococcus multilocularis | neuropeptide receptor A26 | 0.0558 | 0.8292 | 0.8129 |
Toxoplasma gondii | lactate dehydrogenase LDH1 | 0.0631 | 1 | 0.5 |
Plasmodium vivax | malate dehydrogenase, putative | 0.0631 | 1 | 1 |
Trichomonas vaginalis | malate and lactate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Schistosoma mansoni | L-lactate dehydrogenase | 0.0631 | 1 | 1 |
Echinococcus granulosus | neuropeptide s receptor | 0.0558 | 0.8292 | 0.8129 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Trypanosoma brucei | cytosolic malate dehydrogenase | 0.0245 | 0.0871 | 0.5 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Echinococcus granulosus | lactate dehydrogenase a | 0.0631 | 1 | 1 |
Echinococcus multilocularis | L lactate dehydrogenase B chain | 0.0631 | 1 | 1 |
Plasmodium falciparum | L-lactate dehydrogenase | 0.0631 | 1 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Brugia malayi | Probable malate dehydrogenase, mitochondrial precursor | 0.0245 | 0.0871 | 0.0742 |
Trichomonas vaginalis | malate and lactate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Wolbachia endosymbiont of Brugia malayi | malate dehydrogenase | 0.0631 | 1 | 0.5 |
Echinococcus granulosus | neuropeptide receptor A26 | 0.0558 | 0.8292 | 0.8129 |
Trypanosoma cruzi | cytosolic malate dehydrogenase, putative | 0.0245 | 0.0871 | 0.5 |
Leishmania major | malate dehydrogenase, putative | 0.0631 | 1 | 1 |
Trichomonas vaginalis | malate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Schistosoma mansoni | malate dehydrogenase | 0.0631 | 1 | 1 |
Trichomonas vaginalis | malate and lactate dehydrogenase, putative | 0.0245 | 0.0871 | 1 |
Loa Loa (eye worm) | malate dehydrogenase | 0.0245 | 0.0871 | 0.0742 |
Echinococcus multilocularis | L lactate dehydrogenase | 0.0385 | 0.4195 | 0.3641 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 11.7 uM | PUBCHEM_BIOASSAY: Inhibitors of T-Type Calcium Channel. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID449739, AID463087, AID493021, AID493022, AID493023, AID493041, AID504579, AID504584, AID504619, AID504628] | ChEMBL. | No reference |
Potency (functional) | 4.6535 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Saccharomyces cerevisiae | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.